Ovarian Cancer Clinical Trials

Showing 461-480 of 1,169 trials

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

NCT05065021

The purpose of this research study is to see how useful it is to look at biomarkers in the blood and tumor tissue of participants with ovarian, fallopian tube or primary peritoneal cancer who have previously received treatment with a drug called a PARP inhibitor, and using the results to determine the best treatment for these participants. Biomarkers are molecules such as genes (molecules that contain instructions for the development and function of cells in the body) and proteins that may be used to see how well a body responds to certain treatments.

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+2 more

University Health Network, Toronto40 participantsStarted Feb 2023

Toronto, Ontario, Canada

UNKNOWNPhase 2

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT02489006

This is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer.

Ovarian CancerFallopian Tube CancerNeoadjuvant Treatment+1 more

University Health Network, Toronto71 participantsStarted Jul 2016

Calgary, Alberta, Canada • Ottawa, Ontario, Canada • Toronto, Ontario, Canada +6 more locations

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Related Searches

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Sirius in Gynaecological Laparoscopic Surgery